Strange the talk of exiting while back at current lows.
Each asset 675a, 42x, 216a is currently in contract development and shelf life stability testing and have been for quite some time. This is all necessary data that will be required for further approvals in coming years.
I admit myself that I thought we would have more news flow on these, however as shown with this announcement that the BOD are not simply waiting around, they are very forward thinking and still seem to accomplish more in each quarter than other companies do in a year.
Recently had a different company announce first patient just dosed in a trial that actually opened 18 months ago?!
IHL Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
